Steven Craig Almo

Title: Inventor Spotlight: Steven Craig Almo

Introduction

Steven Craig Almo, based in Pelham, NY, is a noteworthy inventor with a remarkable portfolio that includes 12 patents. His research and innovation are particularly focused on advancements in immunology and infectious diseases, demonstrating his dedication to improving human health through scientific discovery.

Latest Patents

Among his latest patents, Almo has developed engineered PD-1 variants, which encompass isolated polypeptides comprising engineered mutant PD-1 polypeptides, as well as fusion polypeptides that include the mutant. Additionally, he has contributed to bispecific PD-L1 and PD-L2 binding mutant PD-1 polypeptides, along with PD-L2-specific binding mutant PD-1 polypeptides. Another significant patent involves precision activation of HIV-specific CTLs (Cytotoxic T Lymphocytes) aimed at eliminating reactivated latent T cells. This innovation outlines compositions and methods that enhance the in vivo capacity of CD8+ T cells to effectively kill HIV-infected and reactivated latent HIV-infected T cells, ultimately working towards a functional cure for HIV infection.

Career Highlights

Throughout his career, Steven Almo has served reputable institutions, including the Albert Einstein College of Medicine and The Penn State Research Foundation. His work has consistently focused on applying cutting-edge research to real-world challenges in medicine and health.

Collaborations

Almo has collaborated with various experts in his field, including notable coworkers such as Sarah C. Garrett-Thomson and Ronald D. Seidel, III. These collaborations have undoubtedly contributed to the successful realization of his patents and projects.

Conclusion

With his extensive experience and innovative mindset, Steven Craig Almo continues to make significant contributions to the field of immunology. His work not only advances scientific understanding but also holds promising potential for future medical breakthroughs.